DISEASE CATEGORY: Cardiovascular INDICATION: Myocardial infarction (MI) Gene therapies delivering CCL24 or IGF2BP3 could restore cardiac function following MI. RNA-seq analysis identified 874 genes including CCL24 and IGF2BP3 that were upregulated in mouse heart tissue...

A multi-omic study of regenerating neonatal hearts has uncovered novel therapeutic targets for cardiac injury post myocardial infarction. Study leader Eric Olson said the findings serve as a resource for understanding the DNA sequences and...

Nearly half a dozen Korean investment groups joined Oncorus' $79.5 million series B round as part of the company's long-range plan to take its oncolytic virus technology global. Cowen Healthcare Investments and Perceptive Advisors led...

A trio of papers from a UCSD group has found a connection between oxidized lipids and inflammation in atherosclerosis, osteoporosis and ischemia injury, breathing new life into the once popular “oxidation hypothesis” of atherosclerosis. The...

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...

INDICATION: Arthritis In vitro and mouse studies identified a chemokine-targeting single-chain variable fragment (scFv)-based fusion protein that could help treat arthritis. Screening of a scFv library for binding to various human and mouse chemokines, engineering...

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round on Dec. 4 led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The...

Antibody company ChemomAb Ltd. (Tel Aviv, Israel) raised $10 million in a series B round led by OrbiMed Israel and Peter Thiel. SBI Japan-Israel Innovation Fund and Milestone Venture also participated. The company previously raised...

INDICATION: Melanoma Patient sample and mouse studies suggest inhibiting CCR5 or its interactions with CCL3, CCL4 and RANTES could help treat melanoma. In patient tissue samples, the number of CCR5-positive myeloid-derived suppressor cells (MDSC) and...

INDICATION: Wounds Patient sample and mouse studies suggest a topical hydrogel that scavenges MCP-1 , CCL3 , CCL4 and other inflammatory factors could help treat chronic wounds. The hydrogel consisted of star-shaped PEG (starPEG) and glycosaminoglycans containing...